Companies › Good Molecules
3 active drug programs in 3 registered trials: 3 Phase 4; Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Investigational moisturizer Topical moisturizer for skin barrier function | – | Phase 4 | Sensitive Skin | Dec 2026 |
| Chemical SPF 30 Chemical sunscreen (organic UV filters) | – | Phase 4 | Epidermis | Feb 2027 |
| Hybrid D II SPF 30 Hybrid sunscreen (combination of organic and inorganic UV filters) | – | Phase 4 | Epidermis | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07811531 | Investigational moisturizer | Phase 4 | Sensitive Skin | Other | Dec 2026 |
| NCT07789639 | Hybrid D II SPF 30 | Phase 4 | Epidermis | Other | Feb 2027 |
| NCT07789639 | Chemical SPF 30 | Phase 4 | Epidermis | Other | Feb 2027 |
No annotated target.
–
Huons Biopharma Neuren Pharmaceuticals Tetra Discovery Partners Prove pharm Neuraptive Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.